NEW YORK, Sept. 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten public offering of 28,750,000 shares of its common stock, including 3,750,000 shares issued pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of

Grand Cayman, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 1,500,000 of the Company’s ordinary shares (or ordinary share equivalents), series A warrants to purchase up to 1,500,000 ordinary shares and series B warrants to purchase up to 1,500,000 ordinary

– Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far – Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Company”, “We” or “Us”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that Nancy T. Chang, former Tanox, Inc. CEO and proven biotechnology leader, has joined the Immix Biopharma Board of Directors concurrent wi

The pro disc® C Vivo and pro disc® C Nova Cervical Total Disc Replacement (TDR) devices are now certified and CE-marked in accordance with the EU Medical Device Regulation (MDR) – the highest European standard of quality, safety, and performance for medical devices. The pro disc C Vivo and pro disc C Nova Match-the-Disc™ System is the first and only cervical TDR system with two different MDR-certified devices. The pro disc C Vivo and pro disc C Nova devices have been in clinical use internationa

BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will effect a 10-for-1 reverse stock split of Athira’s issued and authorized common stock. Athira’s stockholders previously approved the reverse stock split and granted the board of directors the authority to determine the exac

LOUISVILLE, Ky., Sept. 11, 2025 /PRNewswire/ -- HealthTrackRx, the nation's leading provider of next-morning molecular diagnostic testing, celebrated the official ribbon-cutting of its new campus at UPS Healthcare Labport facility in Louisville yesterday. This $45.5 million investment represents a significant milestone in HealthTrackRx's mission of Getting People Healthier Faster, doubling the company's testing capacity to five million patient samples annually and enabling faster, more affordab

Framework agreement with UniHA enables access to Lunit's breast AI solutions across 1,500+ French public hospitals, in collaboration with Fujifilm SEOUL, South Korea, Sept. 11, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that its breast imaging AI solutions have been selected under a national framework agreement led by UniHA, the largest central public procurement body for French hospitals. Continue Reading Lunit s

Single-cell insights uncover the gene driving recurrence and treatment resistance in meningiomas SEOUL, South Korea, Sept. 11, 2025 /PRNewswire/ --Meningiomas are the most common primary brain tumors, accounting for nearly one-third of all central nervous system (CNS) tumors. While most are benign and manageable, 20–30% progress to high-grade forms that behave aggressively, recur frequently, and resist standard treatments. Recurrence remains a major clinical challenge, as these tumors often retu

No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker data Phase 2a study fully enrolled; Topline data on track for Q3 2025 Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival LA JOLLA, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an inn

OKLAHOMA CITY, Sept. 11, 2025 /PRNewswire/ -- Equality Health is increasing its efforts to prevent HIV by increasing the availability of PrEP (pre-exposure prophylaxis) throughout Oklahoma. This effort is part of the group's ongoing work to make healthcare more accessible and help prevent the spread of HIV. PrEP is a preventive medication that, when taken as prescribed, can reduce the risk of contracting HIV by up to 99%. By broadening the availability of PrEP, Equality Health is offering indivi